Clinical and electrophysiological improvement of adrenomyeloneuropathy with steroid treatment [4]

Journal of Neurology Neurosurgery and Psychiatry

Volumn 74, Issue 6, 2003, Pages 822-823

  Zhang, Li Xin ^a   Bakshi, R ^a   Fine, E ^b   Moser, H W ^c  

^a UNIVERSITY AT BUFFALO   (United States)

^b VA WESTERN NEW YORK HEALTHCARE SYSTEM   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; PREDNISONE; STEROID;

ADRENOLEUKODYSTROPHY; ADULT; CASE REPORT; CLINICAL FEATURE; CORTICOTROPIN BLOOD LEVEL; DEMYELINATING DISEASE; DISEASE CLASSIFICATION; DISEASE COURSE; ELECTROPHYSIOLOGY; HORMONE SUBSTITUTION; HUMAN; LETTER; MALE; PRIORITY JOURNAL; STEROID THERAPY;

ADMINISTRATION, ORAL; ADRENOLEUKODYSTROPHY; ADULT; ANTI-INFLAMMATORY AGENTS; EVOKED POTENTIALS; HUMANS; MALE; PREDNISONE;

EID: 0038692415     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.74.6.822     Document Type: Letter

References (5)

1. Moser HW, Smith KD, Watkins PA, et al. X-linked adrenoleukodystrophy. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. The metabolic and molecular bases of inherited disease, 8th ed. New York: McGraw Hill, 2001:3257-301.
2. Van Geel MM, Bezman L, Loes DJ, et al. Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy. Ann Neurol 2001;49:186-94.
3. Nuwer MR, Packwood JW, Myers LW, et al. Evoked potentials predict the clinical changes in a multiple sclerosis drug study. Neurology 1987;37:1754-61.
4. Peckham RS, Marshall MC, Rosman PM, et al. A variant of adrenomyeloneuropathy with hypothalamic-pituitary dysfunction and neurologic remission after glucocorticoid replacement therapy. Am J Med 1982;72:173-6.
5. Dunne JW. Neurological improvement of adrenomyeloneuropathy after steroid replacement therapy. Muscle Nerve 1993;16:1133-4.